ClinicalTrials.gg
CompletedNCT06454240Updated Apr 28, 2026

A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps

A Phase 2 interventional study of lunsekimig and placebo in Chronic Rhinosinusitis With Nasal Polyps, sponsored by Sanofi. Completed at 29 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Nasal Polyps by Sanofi — none open to participants now, 4 under way, 3 of them phase 3. Nasal Polyps · Sanofi.

Enrollment
5th of 12
79 · median 69
Started
2024
with 1 other
Phase 2
4 of 13
none open now
Registered
7th of 13
by date

Among the 13 studies in Nasal Polyps by Sanofi, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 4 in phase 2, and was the 7th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

None of the 13 studies in Nasal Polyps by Sanofi is open now. The open studies under Nasal Polyps, anywhere →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Nasal Polyps by Sanofi as a file.
02

Study summary

This is a parallel, Phase 2, 2-arm, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study for treatment of CRSwNP.

The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous lunsekimig in adult participants (aged 18 to 70 years, inclusive) with CRSwNP who are inadequately controlled on intranasal corticosteroid treatment. Participants with and without co-morbid asthma will be included in the study, and lung function will be assessed in both groups.

The study duration will be up to approximately 40 weeks per participant, including 4 weeks of screening run-in period, 24 weeks of intervention period, and 12 weeks of follow-up.

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- A minimum bilateral nasal polyp score of 5 out of a maximum score of 8 for both nostrils (with at least a score of 2 for each nostril) despite use of intranasal treatment for at least 2 months prior to screening

Ongoing symptoms for at least 2 months prior to screening, including:

  • Nasal congestion, blockage, or obstruction with moderate or severe symptom severity at screening (Score 2 or 3 on NC Score) and a weekly average severity score of at least 1 (range 0 to 3) at randomization (NC Score: 0=no symptoms, 1=mild, 2=moderate, and 3=severe).
  • At least 1 of the following 2 symptoms: (1) partial loss of smell (hyposmia) or total loss of smell (anosmia); (2) anterior and/or posterior rhinorrhea.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Patient who has received any therapies such as for example systemic , anti-IgE therapy, monoclonal antibody and some others in the specified timeframe(s) prior to the screening visit
  • Patients who have undergone any nasal/sinus surgery within 6 months before screening or for whom NPS cannot be determined accurately on endoscopy due to anatomic changes to the nasal cavity from past nasal/sinus surgery
  • Patients with conditions/concomitant diseases making them non evaluable for the primary efficacy endpoint
  • Signs or a CT scan suggestive of Allergic fungal rhinosinusitis
  • Active/chronic helminthic infection
  • History of (HIV) infection or positive HIV screen (Anti-HIV- and HIV-2 antibodies) at screening visit
  • Patients with positive or indeterminate surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or antibody at screening visit NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
79 participants (actual)

Study arms

  • Placebo comparator
    Arm 1

    Participant will receive placebo subcutaneous (SC) every 4 weeks and intranasal mometasone furoate nasal spray (MFNS) for 24 weeks.

    Drug: placebo

  • Experimental
    Arm 2

    Participant will receive lunsekimig subcutaneous (SC) every 4 weeks and intranasal mometasone furoate nasal spray (MFNS) for 24 weeks.

    Drug: lunsekimig

Interventions

  • Pharmaceutical form:solution for injection-Route of administration:subcutaneous

    Also known as: SAR443765

  • Drugplacebo

    Pharmaceutical form:solution for injection-Route of administration:subcutaneous

06

What researchers measure

Primary outcomes

  1. Change in bilateral endoscopic nasal polyp score (NPS).

    This score (NPS) is the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. NP is graded based on polyp size where: 0- no polyps and 4- large polyps causing complete obstruction of the inferior nasal cavity.

    Time frame: From baseline to Week 24

Secondary outcomes

  1. Change in patient-reported nasal congestion/obstruction score

    Patient-reported nasal congestion/obstruction score. Score is using a 0-3 categorical scale where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms

    Time frame: From baseline to Week 24

  2. Change in Lund-Mackay CT score

    Lund-Mackay system is based on scoring bilateral areas of opacification with points given for degree of sinus opacification in each reagion: 0 = normal, 1 = partial opacification, 2 = total opacification.

    Time frame: From baseline to Week 24

  3. Change in the percent of maxillary sinus volume occupied by disease on CT scan.

    Time frame: From baseline to Week 24

  4. Change in SNOT-22 total score.

    The SNOT-22 is a 22-item health-related outcomes assessment. The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).

    Time frame: From baseline to Week 24

  5. Change in patient-reported total symptom score (nasal congestion/obstruction, anterior or posterior rhinorrhea, and loss of smell).

    Score is using a 0-3 categorical scale where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms

    Time frame: From baseline to Week 24

  6. Change in patient-reported anterior rhinorrhea and posterior rhinorrhea score

    0-3 scale, component of patient-reported total symptom score

    Time frame: From baseline to Week 24

  7. Change in rhinosinusitis visual analog scale (VAS).

    The VAS for rhinosinusitis is used to evaluate the total severity (30). Rhinosinusitis disease can be divided into Mild, Moderate and Severe based on total severity VAS score (0 to 10 cm): * MILD = VAS 0 to 3. * MODERATE = VAS \>3 to 7. * SEVERE = VAS \>7 to 10. The participant is asked to indicate along a 10 centimeter straight horizontal line (VAS) the answer to the question: "How troublesome are your symptoms of your rhinosinusitis". The VAS ranks from 0 (Not troublesome) to 10 (Worst thinkable troublesome) and is measured in centimeters.

    Time frame: From baseline to Week 24

  8. Change in University of Pennsylvania Smell Identification Test (UPSIT) score.

    The UPSIT test is a rapid and easy-to-administer method to quantitatively assess human olfactory function. The test consists of four booklets, each containing 10 odorants with one odorant per page. Above each odorant strip is a multiple-choice question with four alternative words to describe the odour. Score depends on the amount of answers out of 40 possible correct answers.

    Time frame: From baseline to Week 24

  9. Change in patient-reported loss of smell score

    0-3 scale, component of patient-reported total symptom score

    Time frame: From baseline to Week 24

  10. Serum lunsekimig concentrations

    Time frame: From baseline to end of study (approximately 36 weeks)

  11. Anti-drug antibodies (ADA) against lunsekimig

    Time frame: From baseline to end of study (approximately 36 weeks)

  12. Incidence of participants with treatment-emergent adverse events (TEAEs)

    Time frame: From baseline to end of study (approximately 36 weeks)

  13. Incidence of participants with adverse events of special interest (AESI)

    Time frame: From baseline to end of study (approximately 36 weeks)

  14. Incidence of participants with serious adverse events (SAEs)

    Time frame: From baseline to end of study (approximately 36 weeks)

  15. Change in asthma control questionnaire (ACQ-5)

    ACQ-5 is Asthma control questionnaire assessing symptoms. Lower score shows better asthma control

    Time frame: From baseline to Week 24

  16. Change in pre-bronchodilator forced expiratory volume in the first second (pre-BD FEV1)

    Time frame: From baseline to Week 24

  17. Change in pre-BD percent predicted FEV1

    Time frame: From baseline to Week 24

07

Study locations

29 sites
  • Allergy & Rheumatology- Site Number : 8400005
    La Jolla, California 92037, United States
  • Sacramento Ear Nose & Throat - Roseville- Site Number : 8400003
    Roseville, California 95661, United States
  • Senta Clinic- Site Number : 8400025
    San Diego, California 92018, United States
  • James A Haley Veterans' Hospital- Site Number : 8400015
    Tampa, Florida 33612, United States
  • Emory University Hospital Midtown- Site Number : 8400012
    Atlanta, Georgia 30308, United States
  • The Allergy Group - Asthma & Allergy Boise- Site Number : 8400002
    Boise, Idaho 83706, United States
  • Harvard Medical School - Brigham and Women's Hospital Site Number : 8400016
    Boston, Massachusetts 02115, United States
  • Essential Medical Research- Site Number : 8400020
    Tulsa, Oklahoma 74137, United States
  • McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8400017
    Bellaire, Texas 77401, United States
  • Gary Gross Pharmaceutical Research & Consulting, Inc. Site Number : 8400004
    Dallas, Texas 75231, United States
  • Berkson Medical - McKinney- Site Number : 8400014
    McKinney, Texas 75070, United States
  • Alamo ENT Associates Site Number : 8400001
    San Antonio, Texas 78258, United States
  • Advanced Research Institute - Odgen- Site Number : 8400022
    Ogden, Utah 84405, United States
  • Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400008
    Norfolk, Virginia 23510, United States
  • Investigational Site Number : 0320002
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1121, Argentina
  • Investigational Site Number : 0320003
    Mendoza, 5500, Argentina
  • Investigational Site Number : 0560002
    Ghent, 9000, Belgium
  • Investigational Site Number : 0560001
    Leuven, 3000, Belgium
  • Investigational Site Number : 1000001
    Sofia, 1612, Bulgaria
  • Investigational Site Number : 6160002
    Krakow, Lesser Poland Voivodeship 31-033, Poland
  • Investigational Site Number : 6160001
    Warsaw, Masovian Voivodeship 00-909, Poland
  • Investigational Site Number : 6160005
    Warsaw, Masovian Voivodeship 02-507, Poland
  • Investigational Site Number : 6160003
    Katowice, Silesian Voivodeship 40-611, Poland
  • Investigational Site Number : 6160004
    Poznan, 60-693, Poland
  • Investigational Site Number : 6160007
    Wroclaw, 53-034, Poland
  • Investigational Site Number : 8260004
    Gloucester, Gloucestershire GL1 3NN, United Kingdom
  • Investigational Site Number : 8260003
    Manchester, M13 9WL, United Kingdom
  • Investigational Site Number : 8260001
    Newcastle upon Tyne, NE7 7DN, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Jan 2026, 18 months.

Of 24 phase 2 interventional studies under Nasal Polyps, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 32. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2024
First posted
Jun 12, 2024
StartActual
Jul 17, 2024
Primary completionActual
Jan 29, 2026
CompletionActual
Apr 23, 2026
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06454240
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 12, 2024
Start date
Jul 17, 2024
Primary completion
Jan 29, 2026
Completion
Apr 23, 2026
Last update
Apr 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lunsekimig

Start the discussion